{"prompt": "['PRODUCT: MK-7902 (E7080/lenvatinib) and MK-3475 (pembrolizumab)', '72', 'PROTOCOL/AMENDMENT NO.: 007-06 (E7080-G000-314)', 'Bisphosphonates or denosumab', 'Antihypertensive therapy (including additional antihypertensive treatment as', 'appropriate if BP increases once the participant is enrolled)', '6.5.2', 'Prohibited Concomitant Medications', 'Participants are prohibited from receiving the following therapies during the screening and', 'treatment phases of the study:', 'Concurrent anticancer therapies, such as chemotherapy, targeted therapies, antitumor', 'interventions (surgical resection, surgical debulking of tumor, etc.), or cancer', 'immunotherapy not specified in this protocol', '- Note: Topical anticancer agents to treat skin lesions (eg, in situ melanoma or', 'squamous cell carcinoma) are allowed, excluding skin metastasis of melanoma.', 'Other concurrent investigational drugs', 'Live or attenuated vaccines within 30 days and while participating in the study. Note:', 'killed vaccines are allowed.', 'Systemic glucocorticoids for any purpose other than those listed in Section 6.5.4.1', 'Radiation therapy for disease control', '-', 'Note: Palliative radiotherapy is permitted for nontarget lesions if considered', 'medically necessary by the treating physician and upon discussion with the', 'Sponsor.', 'For participants who, in an assessment by the investigator, require the use of any of the', 'aforementioned treatments for clinical management, continuation of the study intervention', 'and further participation in the study must be discussed and agreed upon with the Sponsor.', 'If participants receive additional anticancer therapies, this will be judged to represent', 'evidence of PD, and study intervention will be discontinued. These participants should', 'complete all end-of-treatment assessments and continue to be followed for survival during', 'the follow-up period.', '6.5.3 Drug Interactions', 'NOTE: As of Amendment 007-06, lenvatinib and matching placebo have been removed', 'from the study. This section is no longer applicable, but has been left unchanged for', 'reference.', 'There are no DDI-related concomitant medication prohibitions or restrictions.', 'Lenvatinib is not expected to clinically meaningfully alter exposure to CYP3A4/', 'P-glycoprotein (Pgp) substrates based on results from a lenvatinib drug-drug interaction', 'MK-7902-007-06 FINAL PROTOCOL', '15-SEP-2021', 'C', 'Confidential']['PRODUCT: MK-7902 (E7080/lenvatinib) and MK-3475 (pembrolizumab)', '73', 'PROTOCOL/AMENDMENT NO.: 007-06 (E7080-G000-314)', '(DDI) study with midazolam (a sensitive CYP3A and Pgp substrate). Clinical studies also', 'showed that co-administration of lenvatinib with either inducers or inhibitors of', 'CYP3A4/Pgp are not of clinical concern.', 'No drug interaction is expected between pembrolizumab and lenvatinib because of divergent', 'metabolic pathways. Pembrolizumab is a monoclonal antibody and is primarily catabolized', 'like other proteins, while lenvatinib is metabolized by enzymatic (CYP3A and aldehyde', 'oxidase) and nonenzymatic processes (see lenvatinib IB).', '6.5.4', 'Rescue Medications and Supportive Care', 'NOTE: As of Amendment 007-06, lenvatinib and matching placebo have been removed', 'from the study. This section has been updated accordingly.', 'Participants should receive appropriate supportive care measures as deemed necessary by the', 'treating investigator. Suggested supportive care measures for the management of AEs with', 'potential immunologic etiology are outlined in Section 6.6.1.', '6.5.4.1', 'Systemic Corticosteroid Use', 'Systemic corticosteroids are permitted in the following situations:', 'To mediate potential immune-related adverse events (irAEs) as guided in Table 3.', 'As pre- or postmedication to prevent AEs associated with IV contrast.', 'Brief, limited use of systemic corticosteroids (7 days) are permitted where such use', 'is considered SOC (eg, for chronic obstructive pulmonary disease [COPD]', 'exacerbation).', 'Replacement doses of steroids (for example, prednisone 10 mg daily) are permitted', 'while on study, as is the use of local steroid injections and topical steroids.', '6.6', 'Dose Modification', 'NOTE: As of Amendment 007-06, text in this section relating to dose modification and', 'other allowed dose interruptions of lenvatinib/matching placebo is no longer applicable.', 'This section has been updated accordingly.', '6.6.1 Immune-related Events and Dose Modification (Withhold, Treat, Discontinue)', '6.6.1.1', 'Dose Modification and Toxicity Management for Immune-related AEs', 'Associated with Pembrolizumab', 'AEs associated with pembrolizumab exposure may represent an immune-related response.', 'These irAEs may occur shortly after the first dose or several months after the last dose of', 'pembrolizumab treatment and may affect more than one body system simultaneously.', 'Therefore, early recognition and initiation of treatment is critical to reduce complications.', 'MK-7902-007-06 FINAL PROTOCOL', '15-SEP-2021', 'C', 'Confidential']\n\n###\n\n", "completion": "END"}